A5078145518- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- SARS-CoV-2 detection and testing
- Viral gastroenteritis research and epidemiology
- COVID-19 epidemiological studies
- Immune responses and vaccinations
- Viral Infections and Immunology Research
- Influenza Virus Research Studies
- Virology and Viral Diseases
- Hepatitis C virus research
University College Dublin
2021-2023
Albert Einstein College of Medicine
2021
St. Vincent's University Hospital
2021
SARS-CoV-2 neutralising antibodies provide protection against COVID-19. Evidence from early vaccine trials suggested binding antibody thresholds could serve as surrogate markers of capacity, but whether these predict sufficient capacity variants concern (VOCs), and this is impacted by or infection history remains unclear. Here we analyse individuals recovered from, vaccinated with hybrid immunity SARS-CoV-2. An NT50 ≥ 100 IU confers in trials, however, VOC induce a reduction NT50, use 1000...
Arthritogenic alphaviruses are globally distributed, mosquito-transmitted viruses that cause rheumatological disease in humans and include Chikungunya virus (CHIKV), Mayaro (MAYV), others. Although serological evidence suggests some antibody-mediated heterologous immunity may be afforded by alphavirus infection, the extent to which broadly neutralizing antibodies protect against multiple arthritogenic elicited during natural infection remains unknown. Here, we describe isolation...
Abstract Quantifying neutralising capacity of circulating SARS-COV-2 antibodies is critical in evaluating protective humoral immune responses generated post-infection/post-vaccination. Here we describe a novel medium-throughput flow cytometry-based micro-neutralisation test to evaluate Neutralising Antibody (NAb) against live SARS-CoV-2 Wild Type and Variants Concern (VOC) convalescent/vaccinated populations. Flow Cytometry-Based Micro-Neutralisation Test (Micro-NT) was performed 96-well...
Quantifying neutralising capacity of circulating SARS-COV-2 antibodies is critical in evaluating protective humoral immune responses generated post-infection/post-vaccination. Here we describe a novel medium-throughput flow cytometry-based micro-neutralisation test to evaluate Neutralising Antibody (NAb) against live SARS-CoV-2 Wild Type and Variants Concern (VOC) convalescent/vaccinated populations. Flow Cytometry-Based Micro-Neutralisation Test (Micro-NT) was performed 96-well plates using...
Abstract Background Although SARS-CoV-2 neutralising antibodies protect against severe COVID-19, whether circulating IgG titres reflect underlying host capacity to neutralise wild type (WT) and variants of concern (VOC) what threshold reflects sufficient remains unclear. Methods In plasma from individuals in the All Ireland Infectious Diseases Cohort, we measured anti receptor binding domain (RBD) by a micro-neutralisation assay, which determined maximum dilution maintain 50% inhibition...
Abstract Background Quantifying neutralising capacity of circulating SARS-COV-2 antibodies is critical in evaluating protective humoral immune responses generated post-infection/post-vaccination. Here we describe a novel medium-throughput flow cytometry based micro-neutralisation assay to evaluate Neutralising Antibody (NAb) against live SARS-CoV-2 Wild Type (D641G) and Variants Concern (VoC) convalescent/vaccinated populations. Methods Micro-Neutralisation (Micro-NT) was performed 96-well...